Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20008986 | 1.00 | SMN1; SMN2 (0.37) | SMN1; SMN2HRH3CYP2D6KCNH2GRM5 | |
| SCHEMBL17856434 | 0.88 | SMN1; SMN2 (0.37) | SMN1; SMN2 | |
| SCHEMBL21722669 | 0.83 | HRH3 (0.33) | HRH3CYP2D6KCNH2 | |
| SCHEMBL15196701 | 0.82 | ALDH1A1 (0.42) | HRH3CYP2D6KCNH2 | |
| SCHEMBL26203667 | 0.80 | ALDH1A1 (0.32) | HRH3CYP2D6KCNH2 | |
| SCHEMBL7851975 | 0.80 | HRH3 (0.41) | HRH3 | |
| SCHEMBL20009059 | 0.80 | GRM5 (0.35) | SMN1; SMN2HRH3CYP2D6KCNH2GRM5 | |
| SCHEMBL20682344 | 0.79 | TSHR (0.38) | KCNH2GRM5 | |
| SCHEMBL20009056 | 0.79 | HRH3 (0.37) | HRH3CYP2D6KCNH2 | |
| SCHEMBL26203664 | 0.79 | DPP4 (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10421756-B2 | Heterobicyclic N-aminophenyl-amides as inhibitors of histone deacetylase | RODIN THERAPEUTICS, INC. (US) | 2019-09-24 | — | — | US | disclosed |
| US-20180194760-A1 | HETEROBICYCLIC N-AMINOPHENYL-AMIDES AS INHIBITORS OF HISTONE DEACETYLASE | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2018-07-12 | — | — | US | disclosed |
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-03-29 | — | — | US | disclosed |
| WO-2017007755-A1 | HETEROBICYCLIC N-AMINOPHENYL-AMIDES AS INHIBITORS OF HISTONE DEACETYLASE | RODIN THERAPEUTICS, INC. (US) | 2017-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180194760-A1 | HETEROBICYCLIC N-AMINOPHENYL-AMIDES AS INHIBITORS OF HISTONE DEACETYLASE | HDAC2, HDAC1, HDAC5 | SMN1; SMN2 1390/4885HRH3 165/4885CYP2D6 3549/4885 |
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | SMARCC1, SMARCC2, SMARCA4 | SMN1; SMN2 176/4885HRH3 203/4885CYP2D6 4116/4885 |
| US-10421756-B2 | Heterobicyclic N-aminophenyl-amides as inhibitors of histone deacetylase | HDAC2, HDAC1, HDAC5 | SMN1; SMN2 1390/4885HRH3 165/4885CYP2D6 3549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.